L19IL2 and L19TNF for advanced basal cell carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, L19IL2 and L19TNF, injected directly into advanced basal cell carcinoma tumors that cannot be treated with surgery or radiation. The goal is to see if these drugs can shrink the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of skin cancer called basal cell carcinoma that is advanced and cannot be removed with surgery or treated with radiation.
- You have at least one skin tumor that can be injected with the study drug.
- You have not had prior treatment with hedgehog inhibitors or checkpoint inhibitors (like vismodegib or Keytruda).
- You are generally healthy enough to walk and take care of yourself (ECOG performance status 0 or 1).
- Your blood tests show adequate kidney and liver function, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination drug (L19IL2/TNF) given as injections into skin tumors. It is for people with advanced basal cell carcinoma that has worsened after or cannot tolerate standard treatments.
This trial tests a combination of two drugs, L19IL2 and L19TNF, which are injected directly into skin tumors. It is for patients with advanced cutaneous squamous cell carcinoma that has not responded to or cannot tolerate immune checkpoint inhibitor therapy.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This Phase 1 trial studies the safety of an investigational drug called IL-12-L19L19 and looks for early signs it may help control advanced (metastatic) solid tumors. It is designed for people whose cancer has continued to grow even after treatment with immune “checkpoint” therapies.
Hear when a new Locally Advanced Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.